摘要
目的 :探讨膀胱癌组织中 ,多药耐药相关因子 (P- gp、GST- π,TOPO )的表达水平及其临床意义。方法 :免疫组化链霉菌素 -生物素 (S- P)法对术前未使用过化疗、放疗及免疫治疗的原发膀胱癌 6 0例 ,膀胱癌旁组织 4 0例及行腔内化疗后复发的膀胱癌组织 30例进行检测。结果 :P- gp与 GST-π在癌中的表达率高于癌旁组织 ,且原发癌中的表达要低于复发癌 ,TOPO 则反之 (P<0 .0 5 )。P- gp,GST- π的表达随着癌分化程度减低而表达增高 ,TOPO 的表达随着癌分化程度减低而表达减低 ,各耐药相关因子联合表达在不同分化程度癌中 ,大致随着癌分化程度减低和复发而表达增高 (P>0 .0 5 ) ,但其中 P- gp与 GST-π联合表达在原发与复发癌组织中有明显差异 (P<0 .0 5 )。原发膀胱癌中 P- gp与 GST- π的表达相关 (P<0 .0 1)。结论 :膀胱癌中 P- gp与 GST- π的高表达 ,TOPO 的低表达可能是肿瘤复发化疗失败的重要原因。临床上对 3种以上耐药相关因子的综合检测意义重大 ,有助于指导临床对膀胱癌的化疗。
Objective:To investigate the expressions of multidrug resistance (MDR) P-gp, GST-π and TOPO Ⅱ in bladder carcinoma.Methods:The expressions of P-gp, GST-π and TOPO Ⅱ were studied by S-P immunohistochemical technical in 60 primary bladder carcinoma which had not been treated by chemotherapy,radiotherapy and immunotherapy before surgery,40 para-cancinoma tissues, and 30 recurrent bladder carcinoma which had been treated by perfusion chemotherapy.Results:The expressions of P-gp and GST-π in cancinoma were higher than those in para-cancinoma,and the expressions in primary carcinoma were lower than those in recurrent carcinoma. The expression of TOPO Ⅱ was just the opposite.All about them had significant difference(P<0.05). The expressions of P-gp and GST-π and the combined expressions of P-gp, GST-π and TOPO Ⅱ increased with the degree of cancinoma turning down, the expression of TOPO Ⅱ turned down with the degree of cancinoma turn down, but they had no significant difference(P>0.05). The combined expressions of P-gp, GST-πand TOPO Ⅱ in different differentiation groups had no significant difference(P>0.05), except of the combined expressions of P-gp and GST-πbetween primary and recurrent bladder cancinoma. The expressions of P-gp and GST-π in primary bladder carcinoma had correlation(P<0.01).Conclusion:The higher expressions of P-gp, GST-π and the lower expression of TOPO Ⅱ in bladder carcinoma may be important cause of recurrent bladder carcinoma after being treated by perfusion chemotherapy. To examine these factor clinically,is beneficial to the treatment of bladder carcinoma chemotherapeutically.
出处
《南通医学院学报》
2004年第1期9-11,共3页
ACTA Academiae Medicinae Nantong
